

Resource Summary Report

Generated by [RRID](#) on Jul 31, 2026

NF-kappa-B1 p105 Antibody

RRID:AB_2282895

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4717, RRID:AB_2282895

Antibody Information

URL: http://antibodyregistry.org/AB_2282895

Proper Citation: Cell Signaling Technology Cat# 4717, RRID:AB_2282895

Target Antigen: NFkB1

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10310196, AB_10828485, AB_2282895.

Antibody Name: NF-kappa-B1 p105 Antibody

Description: This polyclonal targets NFkB1

Target Organism: rat, mouse, human

Antibody ID: AB_2282895

Vendor: Cell Signaling Technology

Catalog Number: 4717

Record Creation Time: 20250820T012809+0000

Record Last Update: 20250820T110038+0000

Ratings and Alerts

No rating or validation information has been found for NF-kappa-B1 p105 Antibody.

No alerts have been found for NF-kappa-B1 p105 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhang H, et al. (2025) De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer. Nature communications, 16(1), 6987.

Osei-Amponsa V, et al. (2024) hRpn13 shapes the proteome and transcriptome through epigenetic factors HDAC8, PADI4, and transcription factor NF- κ B p50. Molecular cell, 84(3), 522.

Wang ZY, et al. (2024) Macrophage ILF3 promotes abdominal aortic aneurysm by inducing inflammatory imbalance in male mice. Nature communications, 15(1), 7249.

Wang Y, et al. (2023) Identification of an IL-1 receptor mutation driving autoinflammation directs IL-1-targeted drug design. Immunity, 56(7), 1485.

Griewahn L, et al. (2023) SPATA2 restricts OTULIN-dependent LUBAC activity independently of CYLD. Cell reports, 42(1), 111961.